A longtime CytomX exec re-emerges at Synthekine, an $82M Stanford spinout
Debanjan Ray apparently had big plans when he quietly left his long-held CFO spot at CytomX back in March 2019. He had gotten his own biotech.
Still in its early stages at the time, that biotech, known as Synthekine, is now ready to start talking. They are breaking out of stealth mode today with $82 million in Series A funding led by Canaan Partners, Samsara BioCapital and The Column Group, and plans to rapidly bring a handful of engineered cytokines, including a rejigged IL-2, into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
